With Big Pharma backing, eFFECTOR plots solid tumor trial with $40M round

John Carroll

More than two years after landing a hefty launch , San Diego-based Therapeutics has scooped up a $ 40 million financing from an expanded group of investors, putting the biotech on track to jump into the clinic with a Phase I/II study of its lead cancer drug.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS